Investment analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) in a research note issued on Friday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Separately, HC Wainwright reaffirmed a "buy" rating and set a $18.00 target price on shares of Vanda Pharmaceuticals in a research note on Monday.
Get Our Latest Report on VNDA
Vanda Pharmaceuticals Price Performance
NASDAQ:VNDA remained flat at $4.81 during mid-day trading on Friday. The company had a trading volume of 412,260 shares, compared to its average volume of 1,223,788. The firm's 50-day moving average is $4.86 and its 200 day moving average is $5.19. The firm has a market cap of $280.46 million, a price-to-earnings ratio of -17.18 and a beta of 0.76. Vanda Pharmaceuticals has a 52 week low of $3.46 and a 52 week high of $6.75.
Insider Activity at Vanda Pharmaceuticals
In related news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now directly owns 44,857 shares of the company's stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.90% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Institutional investors and hedge funds have recently made changes to their positions in the business. Meeder Asset Management Inc. bought a new position in shares of Vanda Pharmaceuticals during the second quarter valued at $39,000. ORG Wealth Partners LLC bought a new stake in Vanda Pharmaceuticals during the 3rd quarter valued at about $40,000. China Universal Asset Management Co. Ltd. raised its holdings in Vanda Pharmaceuticals by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock worth $53,000 after buying an additional 4,374 shares during the last quarter. XTX Topco Ltd purchased a new position in Vanda Pharmaceuticals in the second quarter worth about $75,000. Finally, Intech Investment Management LLC bought a new position in shares of Vanda Pharmaceuticals in the third quarter worth approximately $84,000. Institutional investors own 88.14% of the company's stock.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Recommended Stories
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
